Nanotechnology-based therapeutic formulations in the battle against animal coronaviruses: an update
Source abstract
Abstract
Outbreak of infectious diseases imposes a serious threat to human population and also causes a catastrophic impact on global economy. Animal coronaviruses remain as one of the intriguing problems, known to cause deadly viral diseases on economically important animal population, and also these infections may spread to other animals and humans. Through isolation of the infected animals from others and providing appropriate treatment using antiviral drugs, it is possible to prevent the virus transmission from animals to other species. In recent times, antiviral drug-resistant strains are being emerged as a deadly virus which are known to cause pandemic. To overcome this, nanoparticles-based formulations are developed as antiviral agent which attacks the animal coronaviruses at multiple sites in the virus replication cycle. Nanovaccines are also being formulated to protect the animals from coronaviruses. Nanoformulations contain particles of one or more dimensions in nano-scale (few nanometers to 1000 nm), which could be inorganic or organic in nature. This review presents the comprehensive outline of the nanotechnology-based therapeutics formulated against animal coronaviruses, which includes the nanoparticles-based antiviral formulations and nanoparticles-based adjuvant vaccines. The mechanism of action of these nanoparticles-based antivirals against animal coronavirus is also discussed using relevant examples. In addition, the scope of repurposing the existing nano-enabled antivirals and vaccines to combat the coronavirus infections in animals is elaborated.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Viral gastroenteritis research and epidemiology · Animal Virus Infections Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (97)
Show source-provided references
1. Astudillo VM, Rosenberg FJ (1983) Relationships between animal viral diseases and socio-economic development. Revue Scientifique et Technique 2:1013–36. https://doi.org/10.20506/rst.2.4.13710.20506/rst.2.4.137 ↗
2. Khamassi Khbou M, Daaloul Jedidi M, Bouaicha Zaafouri F, Benzarti MH (2020) Coronaviruses in farm animals: epidemiology and public health implications. Vet Med Sci 7:322–347. https://doi.org/10.1002/vms3.35910.1002/vms3.359 ↗
3. Thornton PK (2010) Livestock production: recent trends, future prospects. Philos Trans R Soc B 365:2853–2867. https://doi.org/10.1098/rstb.2010.013410.1098/rstb.2010.0134 ↗
4. Birthal PS, Rao PP (2002) Economic contributions of the livestock subsector in India. Technology options for sustainable livestock production in India: proceedings of the Workshop on Documentation, Adoption, and Impact of Livestock Technologies in India, 18–19 Jan 2001, ICRISAT-Patancheru, India. New Delhi 110 012, India and Patancheru 502 324, Andhra Pradesh, India: National Centre for Agricultural Economics and Policy Research and International Crops Research Institute for the Semi-Arid Tropics. 220 pp. ISBN 92–9066–444–4. Order code CPE 137.
5. Karesh WB, Dobson A, Lloyd-Smith JO, Lubroth J, Dixon MA, Bennett M, Aldrich S, Harrington T, Formenty P, Loh EH, Machalaba CC (2012) Ecology of zoonoses: natural and unnatural histories. Lancet 380:1936–1945. https://doi.org/10.1016/S0140-6736(12)61678-X10.1016/S0140-6736(12)61678-X ↗
6. Espinosa R, Tago D, Treich N (2020) Infectious diseases and meat production. Environ Resour Econ 76:1019–1044. https://doi.org/10.1007/s10640-020-00484-310.1007/s10640-020-00484-3 ↗
7. Lindahl JF, Grace D (2015) The consequences of human actions on risks for infectious diseases: a review. Infect Ecol Epidemiology 5:30048. https://doi.org/10.3402/iee.v5.3004810.3402/iee.v5.30048 ↗
8. Parrish CR, Holmes EC, Morens DM, Park EC, Burke DS, Calisher CH, Laughlin CA, Saif LJ, Daszak P (2008) Cross-species virus transmission and the emergence of new epidemic diseases. Microbiol Mol Biol Rev 72:457–470. https://doi.org/10.1128/MMBR.00004-0810.1128/MMBR.00004-08 ↗
9. Murcia P, Donachie W, Palmarini M (2009) Viral pathogens of domestic animals and their impact on biology, medicine and agriculture. Encycl Microbiol 2009:805. https://doi.org/10.1016/B978-012373944-5.00368-010.1016/B978-012373944-5.00368-0 ↗
10. Madhav N, Oppenheim B, Gallivan M, Mulembakani P, Rubin E, Wolfe N (2017) Pandemics: risks, impacts, and mitigation. In: Disease Control Priorities: Improving Health and Reducing Poverty, 3rd edn. The International Bank for Reconstruction and Development / The World Bank, Washington (DC).10.1596/978-1-4648-0527-1_ch17 ↗
11. Burrell CJ, Howard CR, Murphy FA (2016) Fenner and White’s medical virology, Academic Press
12. Woo PC, Lau SK, Huang Y, Yuen KY (2009) Coronavirus diversity, phylogeny and interspecies jumping. Exp Biol Med 234:1117–1127. https://doi.org/10.3181/0903-MR-9410.3181/0903-MR-94 ↗
13. Chan JF, Li KS, To KK, Cheng VC, Chen H, Yuen KY (2012) Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J Infect 65:477–489. https://doi.org/10.1016/j.jinf.2012.10.00210.1016/j.jinf.2012.10.002 ↗
14. Zhang G, Li B, Yoo D, Qin T, Zhang X, Jia Y, Cui S (2021) Animal coronaviruses and SARS-CoV-2. Transbound Emerg Dis 68:1097–1110. https://doi.org/10.1111/tbed.1379110.1111/tbed.13791 ↗
15. Tiwari R, Dhama K, Sharun K, Iqbal Yatoo M, Malik YS, Singh R, Michalak I, Sah R, Bonilla-Aldana DK, Rodriguez-Morales AJ (2020) COVID-19: animals, veterinary and zoonotic links. Vet Q 40:169–182. https://doi.org/10.1080/01652176.2020.176672510.1080/01652176.2020.1766725 ↗
16. Alonso C, Goede DP, Morrison RB, Davies PR, Rovira A, Marthaler DG, Torremorell M (2014) Evidence of infectivity of airborne porcine epidemic diarrhea virus and detection of airborne viral RNA at long distances from infected herds. Vet Res 45:1–5. https://doi.org/10.1186/s13567-014-0073-z10.1186/s13567-014-0073-z ↗
17. Tekes G, Thiel HJ (2016) Feline coronaviruses: pathogenesis of feline infectious peritonitis. Adv Virus Res 96:193–218. https://doi.org/10.1016/bs.aivir.2016.08.00210.1016/bs.aivir.2016.08.002 ↗
18. Licitra BN, Duhamel GE, Whittaker GR (2014) Canine enteric coronaviruses: emerging viral pathogens with distinct recombinant spike proteins. Viruses 6:3363–3376. https://doi.org/10.3390/v608336310.3390/v6083363 ↗
19. Gorbalenya AE, Baker SC, Baric R, Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW, Penzar D (2020) Severe acute respiratory syndrome-related coronavirus: the species and its viruses–a statement of the Coronavirus Study Group. BioRxiv. https://doi.org/10.1101/2020.02.07.937862v110.1101/2020.02.07.937862v1 ↗
20. Kuo L, Masters PS (2013) Functional analysis of the murine coronavirus genomic RNA packaging signal. J Virol 87:5182–5192. https://doi.org/10.1128/JVI.00100-1310.1128/JVI.00100-13 ↗
21. Suzuki T, Otake Y, Uchimoto S, Hasebe A, Goto Y (2020) Genomic characterization and phylogenetic classification of bovine coronaviruses through whole genome sequence analysis. Viruses 12:183. https://doi.org/10.3390/v1202018310.3390/v12020183 ↗
22. Wang Q, Vlasova AN, Kenney SP, Saif LJ (2019) Emerging and re-emerging coronaviruses in pigs. Curr Opin Virol 34:39–49. https://doi.org/10.1016/j.coviro.2018.12.00110.1016/j.coviro.2018.12.001 ↗
23. Colvero LP, Villarreal LYB, Torres CA, Brando PE (2015) Assessing the economic burden of avian infectious bronchitis on poultry farms in Brazil. Rev Sci Tech 34:993–99910.20506/rst.34.3.2411 ↗
24. Dea S, Tijssen P (1989) Detection of turkey enteric coronavirus by enzyme-linked immunosorbent assay and differentiation from other coronaviruses. Am J Vet Res 50:226–231
25. Duarte M, Tobler K, Bridgen A, Rasschaert D, Ackermann M, Laude H (1994) Sequence analysis of the porcine epidemic diarrhea virus genome between the nucleocapsid and spike protein genes reveals a polymorphic ORF. Virology 198:466–476. https://doi.org/10.1006/viro.1994.105810.1006/viro.1994.1058 ↗
26. Compton SR, Ball-Goodrich LJ, Paturzo F, Macy JD (2004) Transmission of enterotropic mouse hepatitis virus from immunocompetent and immunodeficient mice. Comp Med 54:29–35
27. Dhama K, Singh SD, Barathidasan R, Desingu PA, Chakraborty S, Tiwari R, Kumar MA (2014) Emergence of avian infectious bronchitis virus and its variants need better diagnosis, prevention and control strategies: a global perspective. Pak J Biol Sci 17:751–767. https://doi.org/10.3923/pjbs.2014.751.76710.3923/pjbs.2014.751.767 ↗
28. Saif LJ (2004) Animal coronaviruses: lessons for SARS. Learning from SARS: Preparing for the Next Disease Outbreak. The National Academies Press, Washington DC, pp 138–149
29. Wang M, Yan M, Xu H, Liang W, Kan B, Zheng B, Chen H, Zheng H, Xu Y, Zhang E, Wang H (2005) SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis 11:1860. https://doi.org/10.3201/eid1112.04129310.3201/eid1112.041293 ↗
30. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, Luo SW, Li PH, Zhang LJ, Guan YJ, Butt KM (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302:276–278. https://doi.org/10.1126/science.108713910.1126/science.1087139 ↗
31. Zhou P, Fan H, Lan T, Yang XL, Shi WF, Zhang W, Zhu Y, Zhang YW, Xie QM, Mani S, Zheng XS (2018) Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin. Nature 556:255–258. https://doi.org/10.1038/s41586-018-0010-910.1038/s41586-018-0010-9 ↗
32. Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, Kumar S, Bhattacharyya A, Kumar H, Bansal S, Medhi B (2020) Drug targets for corona virus: a systematic review. Indian J Pharmacol 52:56. https://doi.org/10.4103/ijp.IJP_115_2010.4103/ijp.IJP_115_20 ↗
33. Kim Y, Mandadapu SR, Groutas WC, Chang KO (2013) Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease. Antivir Res 97:161–168. https://doi.org/10.1016/j.antiviral.2012.11.00510.1016/j.antiviral.2012.11.005 ↗
34. Kim Y, Lovell S, Tiew KC, Mandadapu SR, Alliston KR, Battaile KP, Groutas WC, Chang KO (2012) Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol 86:11754–11762. https://doi.org/10.1128/JVI.01348-1210.1128/JVI.01348-12 ↗
35. Perera KD, Kankanamalage AC, Rathnayake AD, Honeyfield A, Groutas W, Chang KO, Kim Y (2018) Protease inhibitors broadly effective against feline, ferret and mink coronaviruses. Antivir Res 160:79–86. https://doi.org/10.1016/j.antiviral.2018.10.01510.1016/j.antiviral.2018.10.015 ↗
36. O’Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB, Palmer KE, Barnett BW, Meyerholz DK, Wohlford-Lenane CL, McCray PB Jr (2010) Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol 84:2511–2521. https://doi.org/10.1128/JVI.02322-0910.1128/JVI.02322-09 ↗
37. Wang Y, Sun Y, Wu A, Xu S, Pan R, Zeng C, Jin X, Ge X, Shi Z, Ahola T, Chen Y (2015) Coronavirus nsp10/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis. J Virol 89:8416–8427. https://doi.org/10.1128/JVI.00948-1510.1128/JVI.00948-15 ↗
38. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aal365310.1126/scitranslmed.aal3653 ↗
39. De Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, Van Nieuwkoop S, Bestebroer TM, Van Den Hoogen BG, Neyts J, Snijder EJ (2014) Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58:4875–4884. https://doi.org/10.1128/AAC.03011-1410.1128/AAC.03011-14 ↗
40. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11:1–4. https://doi.org/10.1038/s41467-019-13940-610.1038/s41467-019-13940-6 ↗
41. Heidary F, Gharebaghi R (2020) Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot 73:593–602. https://doi.org/10.1038/s41429-020-0336-z10.1038/s41429-020-0336-z ↗
42. de Melo GD, Lazarini F, Larrous F, Feige L, Kergoat L, Marchio A, Pineau P, Lecuit M, Lledo PM, Changeux JP, Bourhy H (2020) Anti-COVID-19 efficacy of ivermectin in the golden hamster. BioRxiv. https://doi.org/10.1101/2020.11.21.39263910.1101/2020.11.21.392639 ↗
43. Hou XL, Yu LY, Liu J, Wang GH (2007) Surface-displayed porcine epidemic diarrhea viral (PEDV) antigens on lactic acid bacteria. Vaccine 26:24–31. https://doi.org/10.1016/j.vaccine.2007.10.06510.1016/j.vaccine.2007.10.065 ↗
44. Zhang Y, Zhang X, Liao X, Huang X, Cao S, Wen X, Wen Y, Wu R, Liu W (2016) Construction of a bivalent DNA vaccine co-expressing S genes of transmissible gastroenteritis virus and porcine epidemic diarrhea virus delivered by attenuated Salmonella typhimurium. Virus Genes 52:354–364. https://doi.org/10.1007/s11262-016-1316-z10.1007/s11262-016-1316-z ↗
45. Takamura K, Okada N, Ui S, Hirahara T, Shimizu Y (2020) Protection studies on winter dysentery caused by bovine coronavirus in cattle using antigens prepared from infected cell lysates. Can J Vet Res 64:138
46. Yang T, Wang HN, Wang X, Tang JN, Lu D, Zhang YF, Guo ZC, Li YL, Gao R, Kang RM (2009) The protective immune response against infectious bronchitis virus induced by multi-epitope-based peptide vaccines. Biosci Biotechnol Biochem. https://doi.org/10.1271/bbb.8086410.1271/bbb.80864 ↗
47. Ramos AP, Cruz MA, Tovani CB, Ciancaglini P (2017) Biomedical Applications of Nanotechnology. Biophys Rev 9:79–89. https://doi.org/10.1007/s12551-016-0246-210.1007/s12551-016-0246-2 ↗
48. Krishnan S, Dusane A, Morajkar R, Venkat A, Vernekar A (2021) Deciphering the role of nanostructured materials in the point-of-care diagnostics for COVID-19: a comprehensive review. J Mater Chem B. https://doi.org/10.1039/D1TB01182K10.1039/D1TB01182K ↗
49. Kumar M, Kuroda K, Dhangar K, Mazumder P, Sonne C, Rinklebe J, Kitajima M (2020) Potential emergence of antiviral-resistant pandemic viruses via environmental drug exposure of animal reservoirs. Environ Sci Technol 54:8503–8505. https://doi.org/10.1021/acs.est.0c0310510.1021/acs.est.0c03105 ↗
50. Jampílek J, Kráľová K (2019) Nanoformulations: a valuable tool in the therapy of viral diseases attacking humans and animals. In: Rai M, Jamil B (eds) Nanotheranostics. Springer, Cham, pp 137–17810.1007/978-3-030-29768-8_7 ↗
51. Chakravarty M, Vora A (2020) Nanotechnology-based antiviral therapeutics. Drug Deliv Transl Res 11:748–787. https://doi.org/10.1007/s13346-020-00818-010.1007/s13346-020-00818-0 ↗
52. Galdiero S, Falanga A, Vitiello M, Cantisani M, Marra V, Galdiero M (2011) Silver nanoparticles as potential antiviral agents. Molecules 16:8894–8918. https://doi.org/10.3390/molecules1610889410.3390/molecules16108894 ↗
53. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin HS (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16:1–33. https://doi.org/10.1186/s12951-018-0392-810.1186/s12951-018-0392-8 ↗
54. Joshy KS, Snigdha S, George A, Kalarikkal N, Pothen LA, Thomas S (2018a) Poly(vinylpyrrolidone)-lipid based hybrid nanoparticles for antiviral drug delivery. Chem Phys Lipids 210:82–89. https://doi.org/10.1016/j.chemphyslip.2017.11.00310.1016/j.chemphyslip.2017.11.003 ↗
55. Joshy KS, George A, Snigdha S, Joseph B, Kalarikkal N, Pothen LA, Thomas S (2018b) Novel core-shell dextran hybrid nanosystem for anti-viral drug delivery. Mater Sci Eng C Mater Biol Appl 93:864–872. https://doi.org/10.1016/j.msec.2018.08.01510.1016/j.msec.2018.08.015 ↗
56. Gao Y, Kraft JC, Yu D, Ho RJY (2018) Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy. Eur J Pharm Biopharm 138:75–91. https://doi.org/10.1016/j.ejpb.2018.04.01410.1016/j.ejpb.2018.04.014 ↗
57. Prathipati PK, Mandal S, Pon G, Vivekanandan R, Destache CJ (2017) Pharmacokinetic and tissue distribution profile of long acting tenofovir alafenamide and elvitegravir loaded nanoparticles in humanized mice model. Pharm Res 34:2749–2755. https://doi.org/10.1007/s11095-017-2255-710.1007/s11095-017-2255-7 ↗
58. Lin GM, Li L, Panwar N, Wang J, Tjin SC, Wang XM, Yong KT (2018) Non-viral gene therapy using multifunctional nanoparticles: status, challenges, and opportunities. Coord Chem Rev 374:133–152. https://doi.org/10.1016/j.ccr.2018.07.00110.1016/j.ccr.2018.07.001 ↗
59. Ariza-Saenz M, Espina M, Calpena A, Gomara MJ, Perez-Pomeda I, Haro I, Garcia ML (2018) Design, characterization, and biopharmaceutical behavior of nanoparticles loaded with an HIV-1 fusion inhibitor peptide. Mol Pharm 15:5005–5018. https://doi.org/10.1021/acs.molpharmaceut.8b0060910.1021/acs.molpharmaceut.8b00609 ↗
60. Aderibigbe BA (2017) Metal-based nanoparticles for the treatment of infectious diseases. Molecules 22:1370. https://doi.org/10.3390/molecules2208137010.3390/molecules22081370 ↗
61. Rai M, Deshmukh SD, Ingle AP, Gupta IR, Galdiero M, Galdiero S (2016) Metal nanoparticles: the protective nanoshield against virus infection. Crit Rev Microbiol 42:46–56. https://doi.org/10.3109/1040841X.2013.87984910.3109/1040841X.2013.879849 ↗
62. Singh A (2021) Eliciting B cell immunity against infectious diseases using nanovaccines. Nat Nanotechnol 16:16–24. https://doi.org/10.1038/s41565-020-00790-310.1038/s41565-020-00790-3 ↗
63. Ting D, Dong N, Fang L, Lu J, Bi J, Xiao S, Han H (2018) Multisite inhibitors for enteric coronavirus: antiviral cationic carbon dots based on curcumin. ACS Appl Nano Mater 1:5451–5459. https://doi.org/10.1021/acsanm.8b0077910.1021/acsanm.8b00779 ↗
64. Tong T, Hu H, Zhou J, Deng S, Zhang X, Tang W, Fang L, Xiao S, Liang J (2020) Glycyrrhizic-acid-based carbon dots with high antiviral activity by multisite inhibition mechanisms. Small 16:1906206. https://doi.org/10.1002/smll.20190620610.1002/smll.201906206 ↗
65. Lv X, Wang P, Bai R, Cong Y, Suo S, Ren X, Chen C (2014) Inhibitory effect of silver nanomaterials on transmissible virus-induced host cell infections. Biomaterials 35:4195–4203. https://doi.org/10.1016/j.biomaterials.2014.01.05410.1016/j.biomaterials.2014.01.054 ↗
66. Chen YN, Hsueh YH, Hsieh CT, Tzou DY, Chang PL (2016) Antiviral activity of graphene–silver nanocomposites against non-enveloped and enveloped viruses. Int J Environ Res Public Health 13(4):430. https://doi.org/10.3390/ijerph1304043010.3390/ijerph13040430 ↗
67. Du T, Liang J, Dong N, Lu J, Fu Y, Fang L, Xiao S, Han H (2018) Glutathione-capped Ag2S nanoclusters inhibit coronavirus proliferation through blockage of viral RNA synthesis and budding. ACS Appl Mater Interfaces 10:4369–4378. https://doi.org/10.1021/acsami.7b1381110.1021/acsami.7b13811 ↗
68. Du T, Zhang J, Li C, Song T, Li P, Liu J, Du X, Wang S (2020) Gold/silver hybrid nanoparticles with enduring inhibition of coronavirus multiplication through multisite mechanisms. Bioconjug Chem 31:2553–2563. https://doi.org/10.1021/acs.bioconjchem.0c0050610.1021/acs.bioconjchem.0c00506 ↗
69. Zhou Y, Jiang X, Tong T, Fang L, Wu Y, Liang J, Xiao S (2020a) High antiviral activity of mercaptoethane sulfonate functionalized Te/BSA nanostars against arterivirus and coronavirus. RSC Adv 10:14161–14169. https://doi.org/10.1039/D0RA01387K10.1039/D0RA01387K ↗
70. Zhou Y, Tong T, Jiang X, Fang L, Wu Y, Liang J, Xiao S (2020b) GSH-ZnS nanoparticles exhibit high-efficiency and broad-spectrum antiviral activities via multistep inhibition mechanisms. ACS Appl Bio Mater 3:4809–4819. https://doi.org/10.1021/acsabm.0c0033210.1021/acsabm.0c00332 ↗
71. Ng SW, Selvarajah GT, Hussein MZ, Yeap SK, Omar AR (2020) In vitro evaluation of curcumin-encapsulated chitosan nanoparticles against feline infectious peritonitis virus and pharmacokinetics study in cats. BioMed Res Int. https://doi.org/10.1155/2020/301219810.1155/2020/3012198 ↗
72. Hu CM, Chang WS, Fang ZS, Chen YT, Wang WL, Tsai HH, Chueh LL, Takano T, Hohdatsu T, Chen HW (2017) Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus. Sci Rep 7:13043. https://doi.org/10.1038/s41598-017-13316-010.1038/s41598-017-13316-0 ↗
73. Salleh A, Naomi R, Utami ND, Mohammad AW, Mahmoudi E, Mustafa N, Fauzi MB (2020) The potential of silver nanoparticles for antiviral and antibacterial applications: a mechanism of action. Nanomaterials 10:1566. https://doi.org/10.3390/nano1008156610.3390/nano10081566 ↗
74. Staroverov SA, Vidyasheva IV, Gabalov KP, Vasilenko OA, Laskavyi VN, Dykman LA (2011) Immunostimulatory effect of gold nanoparticles conjugated with transmissible gastroenteritis virus. Bull Exp Biol Med 151:436. https://doi.org/10.1007/s10517-011-1350-810.1007/s10517-011-1350-8 ↗
75. Li B, Du L, Yu Z, Sun B, Xu X, Fan B, Guo R, Yuan W, He K (2017) Poly (D, L-lactide-co-glycolide) nanoparticle-entrapped vaccine induces a protective immune response against porcine epidemic diarrhea virus infection in piglets. Vaccine 35:7010–7017. https://doi.org/10.1016/j.vaccine.2017.10.05410.1016/j.vaccine.2017.10.054 ↗
76. Li J, Helal ZH, Karch CP, Mishra N, Girshick T, Garmendia A, Burkhard P, Khan MI (2018) A self-adjuvanted nanoparticle-based vaccine against infectious bronchitis virus. PLoS ONE 13:e0203771. https://doi.org/10.1371/journal.pone.020377110.1371/journal.pone.0203771 ↗
77. Chandrasekar SS, Kingstad-Bakke B, Wu CW, Suresh M, Talaat AM (2020) A novel mucosal adjuvant system for immunization against avian coronavirus causing infectious bronchitis. J Virol 94:e01016-e1020. https://doi.org/10.1128/JVI.01016-2010.1128/JVI.01016-20 ↗
78. Chang SY, Huang KY, Chao TL, Kao HC, Pang YH, Lu L, Chiu CL, Huang HC, Cheng TJ, Fang JM, Yang PC (2021) Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses. Sci Rep 11:1–3. https://doi.org/10.1038/s41598-021-87254-310.1038/s41598-021-87254-3 ↗
79. Jeremiah SS, Miyakawa K, Morita T, Yamaoka Y, Ryo A (2020) Potent antiviral effect of silver nanoparticles on SARS-CoV-2. Biochem Biophys Res Commun 533:195–200. https://doi.org/10.1016/j.bbrc.2020.09.01810.1016/j.bbrc.2020.09.018 ↗
80. Abo-Zeid Y, Ismail NS, McLean GR, Hamdy NM (2020) A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection. Eur J Pharm Sci 153:105465. https://doi.org/10.1016/j.ejps.2020.10546510.1016/j.ejps.2020.105465 ↗
81. Surnar B, Kamran MZ, Shah AS, Dhar S (2020) Clinically approved antiviral drug in an orally administrable nanoparticle for COVID-19. ACS Pharmacol Transl Sci 3:1371–1380. https://doi.org/10.1021/acsptsci.0c0017910.1021/acsptsci.0c00179 ↗
82. Ullah A, Qazi J, Rahman L, Kanaras AG, Khan WS, Hussain I, Rehman A (2020) Nanoparticles-assisted delivery of antiviral-siRNA as inhalable treatment for human respiratory viruses: a candidate approach against SARS-COV-2. Nano Select 1:612–621. https://doi.org/10.1002/nano.20200012510.1002/nano.202000125 ↗
83. Ishak NM, Kamarudin SK, Timmiati SN (2019) Green synthesis of metal and metal oxide nanoparticles via plant extracts: an overview. Mater Res Express 6:112004. https://doi.org/10.1088/2053-1591/ab445810.1088/2053-1591/ab4458 ↗
84. Fatima M, Sadaf Zaidi NU, Amraiz D, Afzal F (2016) In vitro antiviral activity of Cinnamomum cassia and its nanoparticles against H7N3 influenza A virus. J Microbiol Biotechnol 26:151–159. https://doi.org/10.4014/jmb.1508.0802410.4014/jmb.1508.08024 ↗
85. Sharma V, Kaushik S, Pandit P, Dhull D, Yadav JP, Kaushik S (2019) Green synthesis of silver nanoparticles from medicinal plants and evaluation of their antiviral potential against Chikungunya virus. Appl Microbiol Biotechnol 103:881–891. https://doi.org/10.1007/s00253-018-9488-110.1007/s00253-018-9488-1 ↗
86. Haggag EG, Elshamy AM, Rabeh MA, Gabr NM, Salem M, Youssif KA, Samir A, Muhsinah AB, Alsayari A, Abdelmohsen UR (2019) Antiviral potential of green synthesized silver nanoparticles of Lampranthus coccineus and Malephora lutea. Int J Nanomedicine 14:6217. https://doi.org/10.2147/IJN.S21417110.2147/IJN.S214171 ↗
87. Ben Salem AN, Zyed R, Lassoued MA, Nidhal S, Sfar S, Mahjoub A (2012) Plant-derived nanoparticles enhance antiviral activity against coxsakievirus B3 by acting on virus particles and vero cells. Dig J Nanomater Biostructures 7:737–744
88. Yang XX, Li CM, Huang CZ (2016) Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection. Nanoscale 8:3040–3048. https://doi.org/10.1039/C5NR07918G10.1039/C5NR07918G ↗
89. Sreekanth TV, Nagajyothi PC, Muthuraman P, Enkhtaivan G, Vattikuti SV, Tettey CO, Kim DH, Shim J, Yoo K (2018) Ultra-sonication-assisted silver nanoparticles using Panax ginseng root extract and their anti-cancer and antiviral activities. J Photochem Photobiol b: Biology 188:6–11. https://doi.org/10.1016/j.jphotobiol.2018.08.01310.1016/j.jphotobiol.2018.08.013 ↗
90. Meléndez-Villanueva MA, Morán-Santibañez K, Martínez-Sanmiguel JJ, Rangel-López R, Garza-Navarro MA, Rodríguez-Padilla C, Zarate-Triviño DG, Trejo-Ávila LM (2019) Virucidal activity of gold nanoparticles synthesized by green chemistry using garlic extract. Viruses 11:1111. https://doi.org/10.3390/v1112111110.3390/v11121111 ↗
91. Mohamed HE, Afridi S, Khalil AT, Ali M, Zohra T, Akhtar R, Ikram A, Shinwari ZK, Maaza M (2020) Promising antiviral, antimicrobial and therapeutic properties of green nanoceria. Nanomedicine 15:467–488. https://doi.org/10.2217/nnm-2019-036810.2217/nnm-2019-0368 ↗
92. Loutfy SA, Elberry MH, Farroh KY, Mohamed HT, Mohamed AA, Mohamed EB, Faraag AH, Mousa SA (2020) Antiviral activity of chitosan nanoparticles encapsulating curcumin against hepatitis C virus genotype 4a in human hepatoma cell lines. Int J Nanomed 15:2699. https://doi.org/10.2147/IJN.S24170210.2147/IJN.S241702 ↗
93. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html. Accessed 30 May 2021
94. Malik JA, Mulla AH, Farooqi T, Pottoo FH, Anwar S, Rengasamy KR (2021) Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother 111254https://doi.org/10.1016/j.biopha.2021.11125410.1016/j.biopha.2021.111254 ↗
95. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO (2021) SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 6:1–7. https://doi.org/10.1038/s41541-021-00292-w10.1038/s41541-021-00292-w ↗
96. Sarkar PK, Mukhopadhyay CD (2021) Ayurvedic metal nanoparticles could be novel antiviral agents against SARS-CoV-2. Int Nano Lett. https://doi.org/10.1007/s40089-020-00323-910.1007/s40089-020-00323-9 ↗
97. Alphandéry E (2020) The potential of various nanotechnologies for coronavirus diagnosis/treatment highlighted through a literature analysis. Bioconjug Chem 31:1873–1882. https://doi.org/10.1021/acs.bioconjchem.0c0028710.1021/acs.bioconjchem.0c00287 ↗